BioSpace News Archive

Abbott (NYSE: ABT) announced today the creation of the Abbott Center for Malnutrition Solutions, an innovation hub focused on reducing malnutrition around the world.

CYduct Diagnostics, Inc. yesterday filed with OTC Markets its financial results for the fiscal years-ended June 30, 2021 and 2020.

ECRI announces a new partnership with the U.S. Food and Drug Administration (FDA) to improve the safety of medical devices through the use of safer materials.

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received a written response to its meeting request relating to its Type B Pre‑Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (the “FDA”) providing a path for Alzamend’s planned clinical development of AL002.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Phase 1/2a clinical study of its lead product candidate, OpRegen®,

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, announced positive data from Part A of its Phase 2 study of THR-149, a plasma kallikrein inhibitor, for the treatment of DME.

CytoReason and Summit Pharmaceuticals International announced that CytoReason has entered the Japanese market, with its technology being utilized by one of Japan’s top pharmaceutical companies.

Regeneron Pharmaceuticals, Inc. announced that a trial assessing investigational REGEN-COV™ in patients hospitalized with COVID-19 met its primary endpoint.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported data published in the peer reviewed Journal of Wound Care, indicating that the company’s Nexodyn acid-oxidizing solution, developed with APR’s proprietary Tehclo technology, was found to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers.

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release providing a safety update on ZYESAMI /aviptadil) which is being tested in the ACTIV-3b/TESICO phase three study sponsored by the National Institutes of Health.